Latest News - Gilead Sciences
Top Corporates Hub
Gilead Sciences
What Do Analysts Have to Say About Gilead Sciences (GILD) Post Earnings?
19.02.2026 14:54
Gilead Sciences, Inc. (NASDAQ:GILD) is one of the best immunotherapy stocks to buy according to hedge funds. Gilead Sciences, Inc. (NASDAQ:GILD) announced its fiscal Q4 and full year 2025 results on February 10, reporting a strong year marked by the continued growth of Biktarvy and Descovy, along with the successful launch of Yeztugo, the world’s […]
Is Most-Watched Stock Gilead Sciences, Inc. (GILD) Worth Betting on Now?
19.02.2026 14:00
Gilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Pacer’s Cash Cows ETF Might Be The Perfect ETF To Own Right Now | COWZ
17.02.2026 14:03
While the S&P 500 (NYSEARCA:SPY) sits flat year-to-date, the Pacer US Cash Cows 100 ETF (NYSEARCA:COWZ) has surged nearly 7%. This shift reflects growing concerns about expensive technology valuations and concentration risk, with the Magnificent Seven trading above 30x earnings on average while comprising over 30% of the S&P 500. COWZ addresses a specific portfolio ... Pacer’s Cash Cows ETF Might Be The Perfect ETF To Own Right Now | COWZ
Metabolon's Metabolomics Platform Enables Largest Metabolomic Analysis to Date in CAR T-Cell Therapy, Revealing New Insights into Severe Neurotoxicity
17.02.2026 14:00
Metabolon, Inc., the global leader in providing metabolomics solutions advancing a wide variety of life science research, diagnostic, therapeutic development, and precision medicine applications, today announced its industry-leading global metabolomics platform was used by researchers from Kite, a Gilead company, for the most extensive metabolomic study ever conducted in the context of CAR T-cell therapy. Leveraging Metabolon's untargeted Global Discovery Panel, Kite researchers analyzed more th
Gilead to Present New HIV Treatment and Prevention Data at CROI 2026, With a Focus on Expanding Options
17.02.2026 13:30
FOSTER CITY, Calif., February 17, 2026--Gilead Sciences, Inc. (Nasdaq: GILD) today announced details of new clinical and real-world data from its innovative HIV treatment and prevention portfolio and research pipeline that will be presented at the 33rd Conference on Retroviruses and Opportunistic Infections (CROI 2026) being held from February 22-25 in Denver, Colorado. Focusing on expanding therapeutic options to meet the diverse needs of communities affected by HIV, notable late-breaking abstr
5 Insightful Analyst Questions From Gilead Sciences’s Q4 Earnings Call
17.02.2026 05:32
Gilead Sciences ended the fourth quarter with results that exceeded Wall Street revenue expectations, yet the market responded negatively as investors focused on guidance and margin pressures. Management cited strong growth in its HIV business, including a 53% increase in the HIV prevention portfolio and rapid uptake of the new YES2GO injectable, as key drivers. CEO Daniel O’Day noted, “YES2GO is a transformative medicine that we expect to drive durable, steady, and long-term growth in our HIV p
Gilead Sciences (NASDAQ:GILD) Has Announced That It Will Be Increasing Its Dividend To $0.82
14.02.2026 12:08
Gilead Sciences, Inc.'s ( NASDAQ:GILD ) dividend will be increasing from last year's payment of the same period to...
Gilead Sciences Stock Spikes After Q4 Results: Time to Buy?
12.02.2026 00:24
Biotech leader Gilead Sciences (GILD) made headlines on Wednesday, with its stock spiking nearly 6% after delivering favorable Q4 results yesterday evening.
Gilead expects 6% of HIV sales growth in 2026, with $800m Yeztugo target
11.02.2026 13:11
Analysts said that Yeztugo’s forecast, which would represent 433% year-over-year growth, is achievable.
These Stocks Are Today’s Movers: Moderna, Robinhood, Cloudflare, Humana, Lyft, Mattel, Beta Technologies, Gilead, and More
11.02.2026 11:29
Shares in Moderna tumble after the company says the Food and Drug Administration refuses to review a seasonal flu vaccine application.
Cantor Fitzgerald Maintains Overweight on Gilead Sciences, Raises Price Target to $155
11.02.2026 09:43
Cantor Fitzgerald analyst Carter Gould maintains Gilead Sciences (NASDAQ:GILD) with a Overweight and raises the price target from $135 to $155.
Scotiabank Maintains Sector Outperform on Gilead Sciences, Raises Price Target to $177
11.02.2026 09:28
Scotiabank analyst Louis Chen maintains Gilead Sciences (NASDAQ:GILD) with a Sector Outperform and raises the price target from $140 to $177.
Needham Maintains Buy on Gilead Sciences, Raises Price Target to $170
11.02.2026 08:05
Needham analyst Joseph Stringer maintains Gilead Sciences (NASDAQ:GILD) with a Buy and raises the price target from $140 to $170.
GILD Q4 Deep Dive: HIV Prevention and Oncology Advances Drive Mixed Outlook
11.02.2026 05:31
Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) reported Q4 CY2025 results beating Wall Street’s revenue expectations, with sales up 4.7% year on year to $7.93 billion. On the other hand, the company’s full-year revenue guidance of $29.8 billion at the midpoint came in 1.2% below analysts’ estimates. Its non-GAAP profit of $1.86 per share was 1.9% above analysts’ consensus estimates.
Gilead Sciences Inc (GILD) Q4 2025 Earnings Call Highlights: Strong HIV Sales Drive Growth ...
11.02.2026 05:03
Gilead Sciences Inc (GILD) reports robust HIV sales growth and outlines strategic initiatives for 2026, despite facing competitive pressures in cell therapy.
2 Intriguing Medical Stocks to Watch as Q4 Results Approach: EXEL, GILD
10.02.2026 00:12
With their Q4 results approaching after-market hours on Tuesday, February 10, Exelixis (EXEL) and Gilead Sciences (GILD) are two top-performing medical stocks to consider.
Should You Buy Gilead Sciences Before Feb. 10?
09.02.2026 15:04
Will the recent momentum be cut short following the biotech's Feb. 10 earnings release, or will it continue?
Lilly bets again on China drugs; Roche showcases MS data
09.02.2026 11:00
Lilly could pay Innovent Biologics up to $9 billion in a new alliance. Elsewhere, Roche tried to assuage investor concerns about its new multiple sclerosis drug and Roivant shares surged.
Gilead Sciences (GILD) Reports Q4: Everything You Need To Know Ahead Of Earnings
09.02.2026 03:03
Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) will be reporting earnings this Tuesday afternoon. Here’s what you need to know.